Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
News
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two…
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two…
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the…
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the…
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit
Data demonstrates the potential of ‘1805 to reset the immune system through its unique mechanism…
Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit
Data demonstrates the potential of ‘1805 to reset the immune system through its unique mechanism…
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE…
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE…
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody NM3086 for PNH Patients
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated…
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody NM3086 for PNH Patients
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated…
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy…
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy…